Dermatology Times July 2024 Recap

Clearances, Approvals, Updates, and Recommendations

FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine

Pyzchiva will be commercialized by Sandoz in the United States.

ICYMI: FDA Approves RhodoLED XL Lamp Red Light Source for Use in Actinic Keratosis Treatment

Biofrontera's red light source is approved for use in combination with aminolevulinic acid hydrochloride (Ameluz) topical gel, 10%.

FDA Approves Roflumilast Cream 0.15% For Atopic Dermatitis in Patients Aged 6 Years and Older

Patrick Burnett, MD, PhD, provides insights into the significance of Arcutis’ roflumilast cream 0.15% formulation and its impact on pediatric patients.

Arcutis Submits sNDA for Roflumilast Foam to FDA for Scalp and Body Psoriasis

The submission to the FDA is supported by positive results from the ARRECTOR phase 3 trial.

The FDA Approves Deuruxolitinib for Severe Alopecia in Adults

Along with the approval, Sun Pharma is introducing an access program to assist eligible patients in starting and adhering to the treatment.

Big Studies and Big Data

Only 25.5% of Hungarian Dermatologists Report Comfortability in Treating Psychodermatological Patients

As many as 76.5% of participants could not name any psychodermatology resources, while only 58.8% were definitively interested in training on the topic.

Crystal Structure of Bimekizumab Fab Fragment Supports Efficacy of IL-17 Dual Inhibition

Christopher Bunick, MD, PhD, provides insights into new research exploring bimekizumab’s unique binding to IL-17F and IL-17A by analyzing crystals of bimekizumab fragment antigen-binding.

Study Finds Novel Pathogenic Variants, Inflammatory Cytokines, and Activated JAK-STAT Signaling in Patients With Congenital Ichthyosis

The international study represents the most comprehensive analysis of Southeast Asian patients with CI to date and provides a detailed look into specific CI subtypes.

Phase 3 Ruxolitinib Study Shows Higher Rates of Adolescent Repigmentation

David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.

First Human Trial Shows CBD’s UVA-Protective Benefits

The study saw a reduction of 2 major UVA-induced mtDNA deletions associated with skin photoaging.

Market and Pharma News, Drug Watch

New Positive Phase 2 Interim Analysis Confirms Efficacy of denovoSkin for Reconstructive Skin Surgery

Cutiss plans to have full phase 2 data in early 2025.

Innovative Melanoma Treatment Among NCInnovation's $5.2 Million Research Funding Recipients

Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson's research in patients with advanced melanoma.

New Clinical Guidelines for Nonmelanoma Skin Cancer Published by Dermatology Association of Radiation Therapy

The guidelines for BCC and SCC treatment with IGSRT detail diagnosis, staging, contraindications, protocols, and emphasize the essential role of a multidisciplinary team.

Roflumilast Cream 0.15% for Atopic Dermatitis Now Commercially Available

Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.

Strides for Skin Health Equity

Embracing Diversity and Cultural Competence

Adopting diversity management is not just a choice but a pressing need in the evolving health care landscape.

Tapinarof Cream 1% Demonstrates Efficacy in Treating Atopic Dermatitis in Young Patients with Skin of Color

Tapinarof cream 1% has proven to be an effective and safe treatment for atopic dermatitis in diverse populations, according to a poster presented at the SPD's annual meeting.

Australian Analysis Calls for Diversity in Dermatological Research

Researchers noted how historical bias in dermatology research has impacted the understanding and treatment of conditions in darker skin.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.